Claims for Patent: 9,339,036

Summary for Patent: 9,339,036

Title:	Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
Abstract:	The present invention relates to inhibiting or preventing infection and protecting against patency complications after a blood catheter has been inserted in a patient comprising administering to the device a pharmaceutically effective amount of a composition comprising (A) at least one taurinamide derivative, and (B) heparin at a low concentration.
Inventor(s):	Prosl Frank R.
Assignee:	ND Partners, LLC
Application Number:	US14034877
Patent Claims:	1. A locking solution composition for treating and reducing infection and flow reduction in blood catheters , wherein the composition comprises a solution of:a. at least one taurinamide derivative; andb. heparin, in a concentration of 50-2500 units/ml (i) permit blood clotting within the blood catheter, and (ii) reduce taurinamide derivative-induced changes to the character of the clots.2. The composition according to wherein the taurinamide derivative is taurolidine.3. The composition according to further comprising a biologically acceptable acid and a biologically acceptable salt of said acid in a combination that brings the pH of the combination into a range that enhances antimicrobial activity of the taurinamide derivative.4. The composition according to wherein the biologically acceptable acid is chosen from the group consisting of citric acid and lactic acid and the biologically acceptable salt is chosen from the group consisting of citrate and lactate.5. The composition according to wherein the taurinamide derivative is taurolidine claim 3 , the biologically acceptable acid is citric acid claim 3 , the biologically acceptable salt is citrate claim 3 , and the pH range is 5.2 to 6.5.6. A locking solution composition for treating and reducing infection and flow reduction in blood catheters claim 3 , wherein the composition comprises a solution of:a. at least one taurinamide derivative; andb. heparin, in a concentration of 50-2500 units/ml (i) permit blood clotting within the blood catheter, and (ii) reduce the formation of methemoglobin by the interaction of the at least one taurinamide derivative with blood.7. The composition according to wherein the taurinamide derivative is taurolidine.8. The composition according to further comprising a biologically acceptable acid and a biologically acceptable salt of said acid in a combination that brings the pH of the combination into a range that enhances antimicrobial activity of the taurinamide derivative.9. The composition according to wherein the biologically acceptable acid is chosen from the group consisting of citric acid and lactic acid and the biologically acceptable salt is chosen from the group consisting of citrate and lactate.10. The composition according to wherein the taurinamide derivative is taurolidine claim 8 , the biologically acceptable acid is citric acid claim 8 , the biologically acceptable salt is citrate claim 8 , and the pH range is 5.2 to 6.5.11. A locking solution composition for treating and reducing infection and flow reduction in blood catheters claim 8 , wherein the composition comprises a solution of:a. at least one taurinamide derivative; andb. heparin, in a concentration of 50-2500 units/ml (i) permit blood clotting within the blood catheter, and (ii) reduce the formation of blood clots of the type which have a tendency to stick to catheter walls.12. The composition according to wherein the taurinamide derivative is taurolidine.13. The composition according to further comprising a biologically acceptable acid and a biologically acceptable salt of said acid in a combination that brings the pH of the combination into a range that enhances antimicrobial activity of the taurinamide derivative.14. The composition according to wherein the biologically acceptable acid is chosen from the group consisting of citric acid and lactic acid and the biologically acceptable salt is chosen from the group consisting of citrate and lactate.15. The composition according to wherein the taurinamide derivative is taurolidine claim 13 , the biologically acceptable acid is citric acid claim 13 , the biologically acceptable salt is citrate claim 13 , and the pH range is 5.2 to 6.5.16. A locking solution composition for reducing infection and flow reduction in blood catheters claim 13 , wherein the locking solution composition comprises a solution of:a. at least one taurinamide derivative; andb. heparin, in a concentration of 50-2500 units/ml (i) permit blood clotting within the blood catheter, and (ii) reduce fragmentation and adherence of clots and clot fragments to the wall of the blood catheter, thereby enhancing removal of clots and clot fragments during preparation of the catheter for use.17. The composition according to wherein the taurinamide derivative is taurolidine.18. The composition according to further comprising a biologically acceptable acid and a biologically acceptable salt of said acid in a combination that brings the pH of the combination into a range that enhances antimicrobial activity of the taurinamide derivative.19. The composition according to wherein the biologically acceptable acid is chosen from the group consisting of citric acid and lactic acid and the biologically acceptable salt is chosen from the group consisting of citrate and lactate.20. The composition according to wherein the taurinamide derivative is taurolidine claim 18 , the biologically acceptable acid is citric acid claim 18 , the biologically acceptable salt is citrate claim 18 , and the pH range is 5.2 to 6.5.